Victory Pharma
Leveraging science-based heritage to develop and commercialize pharmaceutical products to treat unmet medical needs in the areas of infectious diseases and pain.
Launch date
Employees
Market cap
AUD21.3b
Enterprise valuation
AUD14.6b (Public information from Sep 2024)
Share price
JPY6464 4507.T
Florham Park New Jersey (HQ)
Notable known LPs: Shionogi
Financials
Estimates*
JPY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 333.4b | 297.2b | 335.1b | 426.7b | 435.1b | 55.4b | 57.8b |
% growth | - | (11 %) | 13 % | 27 % | 2 % | (87 %) | 4 % |
EBITDA | 175.2b | 158.7b | 143.5b | 242.0b | 223.3b | - | - |
% EBITDA margin | 53 % | 53 % | 43 % | 57 % | 51 % | - | - |
Profit | 122.2b | 111.9b | 114.2b | 185.0b | 162.0b | - | - |
% profit margin | 37 % | 38 % | 34 % | 43 % | 37 % | - | - |
R&D budget | 47.9b | 54.2b | 73.0b | 102.4b | 102.6b | - | - |
R&D % of revenue | 14 % | 18 % | 22 % | 24 % | 24 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | $118m | Acquisition | |
$7.6m | Grant | ||
Total Funding | AUD11.7m |
Related Content
Recent News about Victory Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.